Farmacias del Ahorro signed a definitive agreement on November 12 to acquire 96.56% of Farmacias Benavides, a stake held by subsidiaries of The Boots Group, according to Expansión. The transaction still requires authorization from the National Antitrust Commission (CNA) and places the chain before a different map of the national pharmaceutical retail market.

The figure that frames the reading is one of scale: the combined network exceeds 3,000 pharmacies, a number close to the 3,115 stores that Farmacias Guadalajara reported at the close of the third quarter of 2025, according to El Financiero. It matters for Mexico because the pharmacy is the most widespread point of contact with the health system: prescriptions are filled there, vital signs are taken, and basic consultations are resolved. In a market with close to 85,000 independent pharmacies, according to the National Statistical Directory of Economic Units (DENUE) cited by Expansión, purchasing scale and logistics determine who can sustain accessible prices on high-turnover medicines.

Benavides contributes 1,132 pharmacies in 203 cities, according to El Financiero, and the resulting network stands above 3,000 units. The distance from Farmacias Similares, with more than 9,000 points of sale, remains wide. Antonio Leonardo Castañón, president of Grupo Farmacias del Ahorro, stated that the purchase "is a strategic milestone that reaffirms this commitment to our country"; Rafael Selvas Silva, the chain's general director, said that "we will leverage the combined strengths of both organizations to expand our reach." Carlos Hernández, director of Analysis at Vardez Capital, told Expansión that greater scale opens room to negotiate with suppliers and optimize costs. While the conditions are met, Benavides will remain under its current management, and it has not been reported whether the commercial identity of its stores will change.

The next checkpoint is the CNA's resolution, which will determine whether the network of more than 3,000 stores materializes. If the closing moves forward, the signal to watch will be the behavior of prices and coverage in the locations where both chains already coincide, because that is where the effect of scale on access to medicines will be measured.

This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.